Floatz logo

ETOMIDATE

Major Depression Disorders

Yeongseok YunSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

234 Active assets in the Major Depression Disorders cohort.

Asset / SponsorPhaseRating
Zelapar
Corium Innovations, Inc.
Phase 4BBB
Risperdal
Johns Hopkins University
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
(1S,2R)-MILNACIPRAN
Allergan
Phase 4BBB

View all 50 →

Same molecule, other indications

ETOMIDATE is also rated in:

choledocholithiasisDormant
BB
Indicative ·
69 / 100
View asset →
pancreatitisDormant
BB
Indicative ·
69 / 100
View asset →
schizophreniaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →